$ARAI

Arrive AI Inc. (ARAI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Arrive AI Inc. (ARAI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 27, 2026, Todd Pepmeier, Chief Financial Officer of Arrive AI Inc. (the “ Company ”), notified the Company of his

Original reporting
Published Jul 31, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ARAI
Neutral
medium confidence
Mentioned
$ARAI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ARAINeutralMed
01

Why it matters

CFO resignation effective Aug. 10, 2026, and director resignation on July 29, 2026, can affect investor confidence in financial reporting continuity and oversight. The filing does not include a replacement officer in the provided text.

02

Market read

This is a fresh, company-specific governance and finance leadership update that can drive near-term sentiment and volatility until succession is clarified.

03

What to watch

Traders should watch for a follow-on 8-K naming an interim or permanent CFO, and whether the board change affects audit or compensation committee composition.

Relevance 6/10Novelty 6/10Timing: after-hours filing on July 31, 2026, ahead of Aug. 10 CFO effective date

Background

The article is an SEC Form 8-K (Item 5.02) reporting executive and director departures and related compensatory arrangements.

Company-level read

Ticker impact

$ARAINeutralMedium confidence
Context

Arrive AI disclosed CFO Todd Pepmeier’s resignation effective Aug. 10, 2026, plus director Laurie Tucker’s resignation, via an Item 5.02 8-K.

Expected impact

Likely short-term volatility around succession details; direction depends on whether a replacement CFO is named elsewhere or later.

Evidence & confidence

The filing confirms resignations and effective dates but does not provide a replacement CFO or detailed rationale, limiting immediate fundamental read-through.

Market effects

No direct sector-wide signal; this is company-specific governance and finance leadership risk.

Limited, as it is a single Nasdaq-listed issuer filing.

Minimal, no cross-border deal or regulatory action described.

Counterpoint

The resignations may be routine or planned, and the company could already have a successor lined up, making the market overreact until replacement details emerge.

Key entities

  • Arrive AI Inc.

    Nasdaq-listed company filing the 8-K reporting CFO and director resignations.

  • Todd Pepmeier

    Chief Financial Officer who resigned effective Aug. 10, 2026.

  • Laurie Tucker

    Director who resigned on July 29, 2026.

  • Daniel S. O’Toole

    Chief Executive Officer signing the 8-K.

Related articles

$ARAIMed

Arrive AI (ARAI) Q2 2026 Earnings Call Transcript

Arrive AI (ARAI) held its Q2 2026 earnings call. Management reported revenue of $14.7 million, a net loss of $14.1 million, and non-GAAP net loss of $4.3 million. Cash and liquid investments were $5.1 million at June 30, with about $1.1 million monthly burn. The company outlined AP3 Plus shipments, a 2027 ramp, and financing capacity via an S-3 and $15 million ATM.

$ARAIMedAI 8/10

Arrive AI unveils Arrive OS, further delivering on Autonomy Unlocked Strategy

Arrive AI (NASDAQ:ARAI) said it has released Arrive OS, the software platform that powers its Arrive Points and connects them via the Arrive Point Network. The company says Arrive Points can gain new capabilities through over-the-air updates, avoiding hardware replacement. Arrive OS is designed to support scalable, interconnected autonomous logistics deployments across enterprise sectors.

$GSMed

Goldman’s board has discussed plan to name John Waldron as next CEO, WSJ reports

Goldman Sachs' board has reportedly discussed a plan for CEO David Solomon to step down and be replaced by COO John Waldron by 2028, with Solomon potentially becoming executive chairman. The bank declined to comment, and shares were unchanged in after-hours trading. According to the Wall Street Journal, the plan requires board approval and could be finalized in the coming months.

$005930.KSMedAI 8/10

Samsung commits $1 billion to help build the infrastructure AI needs

Samsung is investing $1 billion in Helix Digital Infrastructure to support global AI infrastructure development. Helix, backed by investors including KKR and NVIDIA, focuses on AI-enabling infrastructure. Samsung's expertise in technology, construction, and energy storage will aid Helix's projects. Helix aims to meet the growing demand for AI infrastructure from hyperscalers.

$NVDAHighAI 8/10

Nvidia boosts share buyback program by record $150B

Nvidia Corp. plans to spend $150B on share buybacks through 2028, the largest-ever expansion of such a program. The company also plans to increase its dividend. Nvidia cited rapid revenue growth and strong performance of its startup investment portfolio as reasons. It ended its fiscal second quarter with $22.44B in cash and expects sales to increase by 70% in fiscal 2028. The company's revenue growth is driven by its expanding product lineup and successful investment portfolio.

$AZNHighAI 9/10

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

AstraZeneca will invest $2 billion in Summit Therapeutics via convertible preferred shares at a 10% premium. The companies will collaborate on cancer treatments, including a clinical trial for gastrointestinal cancers. Summit's shares rose 18% in after-hours trading, while AstraZeneca's shares remained unchanged. The deal is expected to close this week, according to Summit.